The United Kingdom and the United States have announced a landmark bilateral deal that will guarantee no levies on UK drug products going into the US market.
The Terms of the Pact
As part of the deal, the UK has committed to raise spending on pharmaceuticals through the public health system. This commitment guarantees that tariffs on these key products will stay at zero for a period of the next three years.
This deal comes after recent warnings to dramatically increase import taxes on branded drug products, with potential rates mentioned up to double the cost.
"This agreement with the UK bolsters the global environment for innovative medicines and introduces much-needed balance to American-British medicine commerce," a statement declared.
Trade Importance
Drugs constitute one of the Britain's largest export categories to the America, which is easily the primary destination for major British pharmaceutical firms.
Statistics show that in the one-year period to the end of last September, the UK exported pharmaceutical products totaling billions to the US. This value represented a significant portion of total UK exports in that timeframe.
"This deal safeguards employment, boosts investment and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Key UK Commitments
The pact involves several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a target to increase total NHS spending on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to prevent overspending will be restricted at fifteen percent. In the past, refunds exceeded 20%.
Industry Background
The pact takes place against a ongoing tension between the sector and the British authorities over drug pricing and approval rates.
This friction were intensified by arguments that US consumers were paying several times more for the identical medicines than patients in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been directed toward American operations.
The Science Minister stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
